Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cook Spectrum v. Arrow Arrowguard Blue

This article was originally published in The Gray Sheet

Executive Summary

Cook's central venous catheter impregnated with minocycline and rifampin had one-third the infection rate of Arrow International's catheter impregnated with chlorhexidine and silver sulfadiazine, according to an 817-patient, 12-site study published in the Jan. 7 New England Journal of Medicine. Of the 865 catheters placed into 817 patients, 85% (738) produced culture results that could be evaluated, of which 356 were Cook's and 382 were Arrow's. Twenty-eight of 356 (7.9%) of Spectrum catheters were colonized, versus colonization in 87 of 382 (22.8%) Arrowguard Blue catheters. Fourteen patients also had catheter-related bloodstream infections, of which 3.4% (13) had Arrow devices and 0.3% (1) had a Cook device

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel